|
|
|
|
|
|
| Preventing HIV |
| Treating HIV |
| Living with HIV |
| For service providers |
| For health care providers |
| Access our services |
| Find organizations |
| News and events |
| About CATIE |
| Site map |
| Home |
| CATIE Ordering Centre |
TreatmentUpdate 172Volume 21 Issue 3 2009 March/April I ANTI-HIV AGENTS - A. The 16th CROIThe Conference on Retroviruses and Opportunistic Infections (CROI) is the premier annual HIV scientific meeting. It allows for leading scientists and doctors to present the results of studies, debate controversial ideas and showcase new findings about the treatment and research of HIV/AIDS. In addition, CROI usually has a substantial body of work on co-infections and complications of HIV and its treatment. In recent years, data on the potential of anti-HIV agents to prevent the sexual transmission of HIV has increasingly been featured at the conference. This year’s CROI, held on February 8 to 11 in Montreal, continued the conference’s trend of providing exciting news on many HIV-related topics. Last year, CROI featured emerging data on the side effects of highly active antiretroviral therapy (HAART), particularly heart attacks. While this sounds alarming, we urge our readers to bear in mind that heart attacks are not common in HAART users. Moreover, in some high-income regions, rates of heart attacks are falling among HAART users to levels seen in HIV negative people. This suggests that doctors are gaining experience in preventing this problem. In this issue of TreatmentUpdate, we present information that was highlighted at the 2009 CROI, including issues such as the following:
Created on: 2009 May 1 Author: Hosein SR |
|
| |
|
Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE | |